全文获取类型
收费全文 | 11916篇 |
免费 | 655篇 |
国内免费 | 95篇 |
专业分类
耳鼻咽喉 | 72篇 |
儿科学 | 291篇 |
妇产科学 | 204篇 |
基础医学 | 1394篇 |
口腔科学 | 177篇 |
临床医学 | 735篇 |
内科学 | 3445篇 |
皮肤病学 | 203篇 |
神经病学 | 808篇 |
特种医学 | 385篇 |
外科学 | 2226篇 |
综合类 | 37篇 |
预防医学 | 229篇 |
眼科学 | 80篇 |
药学 | 758篇 |
中国医学 | 28篇 |
肿瘤学 | 1594篇 |
出版年
2023年 | 88篇 |
2022年 | 64篇 |
2021年 | 315篇 |
2020年 | 216篇 |
2019年 | 282篇 |
2018年 | 326篇 |
2017年 | 252篇 |
2016年 | 297篇 |
2015年 | 335篇 |
2014年 | 415篇 |
2013年 | 458篇 |
2012年 | 869篇 |
2011年 | 895篇 |
2010年 | 524篇 |
2009年 | 437篇 |
2008年 | 755篇 |
2007年 | 793篇 |
2006年 | 820篇 |
2005年 | 773篇 |
2004年 | 806篇 |
2003年 | 761篇 |
2002年 | 788篇 |
2001年 | 131篇 |
2000年 | 69篇 |
1999年 | 137篇 |
1998年 | 162篇 |
1997年 | 121篇 |
1996年 | 106篇 |
1995年 | 91篇 |
1994年 | 87篇 |
1993年 | 73篇 |
1992年 | 53篇 |
1991年 | 44篇 |
1990年 | 42篇 |
1989年 | 30篇 |
1988年 | 27篇 |
1987年 | 27篇 |
1986年 | 21篇 |
1985年 | 17篇 |
1984年 | 26篇 |
1983年 | 12篇 |
1982年 | 20篇 |
1981年 | 16篇 |
1980年 | 20篇 |
1979年 | 16篇 |
1978年 | 7篇 |
1977年 | 12篇 |
1976年 | 5篇 |
1975年 | 4篇 |
1974年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
Harada Hideyuki Omori Shota Mori Keita Konno Masahiro Murakami Haruyasu Imagumbai Toshiyuki Fukuda Haruyuki Nakamatsu Kiyoshi Kimura Tomoki Tanabe Hiroaki Fujita Hideki Tatebe Hitoshi Fujitaka Kazunori Nishimura Yasumasa 《International journal of clinical oncology / Japan Society of Clinical Oncology》2022,27(6):1025-1033
International Journal of Clinical Oncology - This multi-institutional clinical trial evaluated the feasibility of intensity-modulated radiotherapy (IMRT) for patients with locally advanced... 相似文献
3.
4.
5.
6.
Kazuko Sakai Takayuki Takahama Mototsugu Shimokawa Koichi Azuma Masayuki Takeda Terufumi Kato Haruko Daga Isamu Okamoto Hiroaki Akamatsu Shunsuke Teraoka Akira Ono Tatsuo Ohira Toshihide Yokoyama Nobuyuki Yamamoto Kazuhiko Nakagawa Kazuto Nishio 《Molecular oncology》2021,15(1):126
The WJOG8815L phase II clinical study involves patients with non‐small cell lung cancer (NSCLC) that harbored the EGFR T790M mutation, which confers resistance to EGFR tyrosine kinase inhibitors (TKIs). The purpose of this study was to assess the predictive value of monitoring EGFR genomic alterations in circulating tumor DNA (ctDNA) from patients with NSCLC that undergo treatment with the third‐generation EGFR‐TKI osimertinib. Plasma samples of 52 patients harboring the EGFR T790M mutation were obtained pretreatment (Pre), on day 1 of treatment cycle 4 (C4) or cycle 9 (C9), and at diagnosis of disease progression or treatment discontinuation (PD/stop). CtDNA was screened for EGFR‐TKI‐sensitizing mutations, the EGFR T790M mutation, and other genomic alterations using the cobas EGFR Mutation Test v2 (cobas), droplet digital PCR (ddPCR), and targeted deep sequencing. Analysis of the sensitizing—and T790M—EGFR mutant fractions (MFs) was used to determine tumor mutational burden. Both MFs were found to decrease during treatment, whereas rebound of the sensitizing EGFR MF was observed at PD/stop, suggesting that osimertinib targeted both T790M mutation‐positive tumors and tumors with sensitizing EGFR mutations. Significant differences in the response rates and progression‐free survival were observed between the sensitizing EGFR MF‐high and sensitizing EGFR MF‐low groups (cutoff: median) at C4. In conclusion, ctDNA monitoring for sensitizing EGFR mutations at C4 is suitable for predicting the treatment outcomes in NSCLC patients receiving osimertinib (Clinical Trial Registration No.: UMIN000022076).
Abbreviations
- CIs
- confidence intervals
- ctDNA
- circulating tumor DNA
- ddPCR
- droplet digital PCR
- EGFR
- epidermal growth factor receptor
- MFs
- mutant fractions
- NGS
- next‐generation sequencing
- NSCLC
- non‐small cell lung cancer
- ORR
- overall response rate
- OS
- overall survival
- PD
- progressive disease
- PFS
- progression‐free survival
- PR
- partial response
- SD
- stable disease
- TKI
- tyrosine kinase inhibitor
7.
8.
Toshiro Hara Rony Chanoch-Myers Nathan D. Mathewson Chad Myskiw Lyla Atta Lillian Bussema Stephen W. Eichhorn Alissa C. Greenwald Gabriela S. Kinker Christopher Rodman L. Nicolas Gonzalez Castro Hiroaki Wakimoto Orit Rozenblatt-Rosen Xiaowei Zhuang Jean Fan Tony Hunter Inder M. Verma Kai W. Wucherpfennig Itay Tirosh 《Cancer cell》2021,39(6):779-792.e11
9.
Shimon Kurasawa Takahiro Imaizumi Shoichi Maruyama Keitaro Tanaka Yoko Kubo Mako Nagayoshi Hiroaki Ikezaki Sadao Suzuki Teruhide Koyama Chihaya Koriyama Aya Kadota Sakurako Katsuura-Kamano Kiyonori Kuriki Kenji Wakai Keitaro Matsuo 《International journal of cancer. Journal international du cancer》2023,153(4):732-741
The association between kidney function and cancer incidence is inconsistent among previous reports, and data on the Japanese population are lacking. It is unknown whether kidney function modifies the cancer risk of other factors. We aimed to evaluate the association of estimated glomerular filtration rate (eGFR) with cancer incidence and mortality in 55 242 participants (median age, 57 years; 55% women) from the Japan Multi-Institutional Collaborative Cohort Study. We also investigated differences in cancer risk factors between individuals with and without kidney dysfunction. During a median 9.3-year follow-up period, 4278 (7.7%) subjects developed cancer. Moderately low and high eGFRs were associated with higher cancer incidence; compared with eGFR of 60-74 ml/min/1.73 m2, the adjusted hazard ratios (HRs) (95% confidence intervals [CIs]) for eGFRs of ≥90, 75-89, 45-59, 30-44 and 10-29 ml/min/1.73 m2 were 1.18 (1.07-1.29), 1.09 (1.01-1.17), 0.93 (0.83-1.04), 1.36 (1.00-1.84) and 1.12 (0.55-2.26), respectively. High eGFR was associated with higher cancer mortality, while low eGFR was not; the adjusted subdistribution HRs (95% CIs) for eGFRs of ≥90 and 75-89 ml/min/1.73 m2 were 1.58 (1.29-1.94) and 1.27 (1.08-1.50), respectively. Subgroup analyses of participants with eGFRs ≥60 and <60 ml/min/1.73 m2 revealed elevated cancer risks of smoking and family history of cancer in those with eGFR <60 ml/min/1.73 m2, with significant interactions. Our findings suggest that the relationship between eGFR and cancer incidence was U-shaped. Only high eGFR was associated with cancer mortality. Kidney dysfunction enhanced cancer risk from smoking. 相似文献
10.
Takahiro Hosokawa Hiroaki Takahashi Yutaka Tanami Yumiko Sato Mayumi Hosokawa Eiji Oguma 《Journal of ultrasound in medicine》2019,38(2):533-538
Portal venous gas is occasionally encountered in children with intestinal pneumatosis, identified on real‐time ultrasound imaging as hyperechoic foci with quick movement. The origin of the portal venous gas can be identified by following the hyperechoic foci along the branches of the portal vein, providing an estimate of the location of intestinal pneumatosis. This approach may be useful for predicting the patient's prognosis. Our report describes 2 cases of portal venous gas while estimating the area of intestinal pneumatosis, which were evaluated with real‐time ultrasound. 相似文献